Chiusura precedente | 4,9200 |
Aperto | 4,9400 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 4,7600 - 5,0700 |
Intervallo di 52 settimane | 4,2900 - 14,4500 |
Volume | |
Media Volume | 411.770 |
Capitalizzazione | 4,419M |
Beta (5 anni mensile) | 1,55 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -14,5600 |
Prossima data utili | 09 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 15,47 |
-- PoNS® devices to be provided to a least five sites in five separate administrative regions within Québec ---- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by patients who have suffered the effects of stroke -- NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today
NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Jeff Mathiesen, Chief Financial Officer, will participate at two upcoming conferences as follows: JonesTrading 2023 Healthcare Summit (1-on-1s Only) Date: Tuesday, October 10, 2023Location: Miami, Florida Investors and attendees who wou
-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossing pharmacy benefit managers (PBMs) –---- PoNS expected to be one of few products with both pharmacy and device codes, providing dual paths for potential reimbursement -- NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a ne